• YAKHAK HOEJI
• /
• v.44 no.6
• /
• pp.521-527
• /
• 2000

The root of Heracleum moellendorffii was extracted with methanol and extract was fractionated with n-hexane, $CHCI_3$ and n-BuOH. Repaeated column chromatography of silica gel, sephadex LH 20 and ODS led to the isolation of ten compounds from n-hexane fraction and n-BuOH fraction. On the basis of spectroscopic evidences, the structures of isolated compounds were identified as isobergapten, psoralen, angelicin, sphondin, xanthotoxin, skimmin, cichoriin, $heratomol-6-O-{\beta}-D-glucopyranoside$, scopolin and apterin.

• Archives of Pharmacal Research
• /
• v.11 no.4
• /
• pp.308-311
• /
• 1988

Nine coumarin dervatives were examined for thier inhibitory effects on bovine lens aldose reductase activity (bovine-LAR). More than 50% inhibition of BLAR activities was observed in the cases of treatments with decursin, decursinol, esculin, isoimperatorin, oxypeucedanine and isobergapten at the concentration of $10^{-4}$M. Especially, BLAR activity was completely inhibited by the treatment of decursin and decursinol at this concentration. At $10^{-5}$ M, only three coumarins-decursin, decursinol and isoimperatorin, were found to have still relatively higher inhibitory effect.

• Natural Product Sciences
• /
• v.23 no.3
• /
• pp.213-216
• /
• 2017

Activity-guided isolation of Heracleum moellendorffii roots led to four coumarin derivatives as acetylcholinesterase inhibitors. The structures of these isolates were characterized by spectroscopic method to be angelicin (1), isobergapten (2), pimpinellin (3), and (3S, 4R)-3, 4-epoxypimpinellin (4). All the isolated compounds 1, 2, 3, and 4 showed moderate inhibition activities against acetylcholinesterase with the $IC_{50}$ values of 10.2, 18.1, 21.5 and $22.9{\mu}M$, respectively. (3S, 4R)-3, 4-Epoxypimpinellin (4) was newly isolated from the plant source.

• The Korean Journal of Physiology and Pharmacology
• /
• v.28 no.1
• /
• pp.59-72
• /
• 2024

To investigate the mechanism of Wenshen Xuanbi Decoction (WSXB) in treating osteoarthritis (OA) via network pharmacology, bioinformatics analysis, and experimental verification. The active components and prediction targets of WSXB were obtained from the TCMSP database and Swiss Target Prediction website, respectively. OA-related genes were retrieved from GeneCards and OMIM databases. Protein-protein interaction and functional enrichment analyses were performed, resulting in the construction of the Herb-Component-Target network. In addition, differential genes of OA were obtained from the GEO database to verify the potential mechanism of WSXB in OA treatment. Subsequently, potential active components were subjected to molecular verification with the hub targets. Finally, we selected the most crucial hub targets and pathways for experimental verification in vitro. The active components in the study included quercetin, linolenic acid, methyl linoleate, isobergapten, and beta-sitosterol. AKT1, tumor necrosis factor (TNF), interleukin (IL)-6, GAPDH, and CTNNB1 were identified as the most crucial hub targets. Molecular docking revealed that the active components and hub targets exhibited strong binding energy. Experimental verification demonstrated that the mRNA and protein expression levels of IL-6, IL-17, and TNF in the WSXB group were lower than those in the KOA group (p < 0.05). WSXB exhibits a chondroprotective effect on OA and delays disease progression. The mechanism is potentially related to the suppression of IL-17 and TNF signaling pathways and the down-regulation of IL-6.